Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
Amneal has made meaningful investments to expand our capacity and capabilities and deliver on our goal to be a significant injectables player.
- Amneal has made meaningful investments to expand our capacity and capabilities and deliver on our goal to be a significant injectables player.
- Importantly, we are building a robust portfolio of injectables that can serve as a reliable solution to market shortages.
- Amneal has tripled its injectables capacity to 60 million units across four manufacturing facilities over the past few years and expects to have over 60 commercial injectable products in 2025.
- Amneal expects to launch two to three new 505(b)(2) injectables per year going forward.